Depending upon the injury or condition, physicians routinely prescribe either immediate-acting or extended-release opioids for pain relief. But patients who don’t know the difference between the two will often take these very different medications in the same manner. And that little mistake can have big consequences.
“If we know that pain and suffering can be alleviated and we do nothing about it, we, ourselves, are tormentors.”
~Primo Levi, concentration camp survivor
Immediate-release opioids are prescription painkillers typically dispensed for episodic or “breakthrough” pain. It is persistent pain that can unpredictably flare up and “break through” most round-the-clock opioid medications. Breakthrough pain is identified by:
Immediate-release opioids are specifically necessary for the treatment of breakthrough pain because they take effect quickly, they last just long enough to get patients through the episode and then wear off, and they are easy to take.
Immediate-release opioids are also called IR, short-acting, or rapid-onset opioids. Because they relieve episodic pain flare-ups, they are also referred to as “rescue medications”.
Breakthrough pain is most-frequently associated with cancer:
Other conditions that linked through breakthrough pain include:
“OxyContin changed the face of addiction in this region. It made addicts out of people who otherwise weren’t. It drove this region crazy.”
~ Dan Smoot, President of the Eastern Kentucky anti-drug organization Operation UNITE
Extended-release opioids are given for the relief of moderate-to-severe pain that requires daily, around-the-clock, long-term treatment. They are typically only prescribed when other pain management options have proven to be inadequate.
Compared to IR painkillers, ER opioids – also referred to as controlled-release or long-acting opioids – typically contain higher doses of medication. And because they deliver the opioid medication over a longer period of time, there is an increased risk of overdose and death.
“We know that there is persistent abuse, addiction, overdose mortality and risk of NOWS (neonatal opioid withdrawal syndrome) associated with IR opioid products. Today, we have taken an important next step in clarifying and making more prominent the known risks of IR opioid medications.”
~ Dr. Douglas Throckmorton, M.D., Deputy Center Director of Regulatory Programs, Center for Drug Evaluation and Research, US Food and Drug Administration
Between 2011 and 2015, researchers at Washington University in St. Louis conducted a survey of over 8300 people entering a drug rehab for opioid abuse. Their goal was to determine if opioid addicts had a preference to immediate-release or extended-release painkillers.
They concluded that BOTH IR and ER opioids were very often abused by individuals who met the criteria for an opioid use disorder:
But when it came to which formulation opioid addicts prefer to use, the disparity was striking. An overwhelming 66.1% of survey respondents had a preference for IR opioids, compared to just 4% preferring ER formulations.
For comparison purposes, 29.9% had no preference.
There were two major reasons self-reported by survey respondents as to why they preferred IR opioids. 73% mentioned the rapid onset and quality of the high experienced. Also, 31.2% indicated that IR medications are easier to divert for misuse than ER opioids.
For example, an IR medication, such as Vicodin, has an onset of action as brief as 10 minutes, reaching peak effect in as little as 30 minutes. On the other hand, an ER opioid like controlled-release OxyContin has an onset of effects at about an hour, and reaches peak effect in around 3 hours.
Recent research published in the December 2013 issue of PAIN reported that:
“Most of what we currently know about…treatment is based on studies that included few or no women at all. Our results show that men and women who are addicted to opioids have very different demographics and health needs, and we need to better reflect this in the treatment options that are available.”
~Dr. Monica Bawor, PhD, McMaster University
There are differences in the people who “typically” choose to abuse certain opioids. For example:
Hydrocodone abusers are more likely to:
On the other hand, oxycodone abusers are more likely to:
Dr. Bawor also says, “We found men and women who are addicted to opioids have very different demographics and health needs, and we need to better reflect this in the treatment options that are available…A rising number of women are seeing treatment for opioid addiction…yet, in many cases, treatment is still geared towards a patient profile that is decades out of date…”
Generally, the warning signs of opioid painkiller misuse can be divided into two categories – physical and behavioral.
Physical Signs –
Behavioral signs –
In addition, opioid painkillers are extremely habit-forming, even when taken exactly as prescribed. This means that when a person who is physically dependent on opioids runs out of their medication, they can suffer harshly-unpleasant symptoms of withdrawal. The discomfort experienced is often what drives the person to seek more drugs.
Opioid withdrawal symptoms –
Opioid withdrawal is not particularly dangerous, but it is both psychologically and physically painful. Most experts recommend the use of anti-craving medications to ease withdrawal and to help prevent relapse.
ANY problematic substance use can result in serious consequences to every area of the abuser’s life. But addiction to opioid painkillers has very specific dangers.
In fact, 80% of heroin abusers started out by misusing opioid pain medications.
“It is clear that not all drug abusers share the same characteristics. The decision to use one drug over another is a complex one, largely attributable to individual differences such as personality, gender, age, and other factors. Prevention and treatment approaches should benefit from this because it may help prescribing physicians determine which drug to prescribe and monitor for abuse.”
~Dr. Theodore Cicero, PhD, Washington University, Department of Psychiatry
These findings clearly demonstrate that there is no single “one-size-fits-all” drug rehab program that will work for 100% of the people, 100% of the time. On the contrary, to be truly effective, opioid rehab must be both individualized and specialized. In other words, any prescribed treatment plan needs to be tailored to the individual after a thorough assessment by a qualified medical professional.
by Albert Fontenot